Schizophrenia News

Following implementation of the peer review prior authorization policy, atypical antipsychotic use significantly decreased among children aged younger than 5 to 8 years in Medicaid programs.

Allergan recently announced that the FDA approved a supplemental New Drug Application for Vraylar for maintenance treatment of schizophrenia.

The FDA recently approved Abilify MyCite, aripiprazole tablets with an ingestible sensor from Otsuka Pharmaceuticals and Proteus Digital Health, to digitally track if patients have ingested medication for the treatment of schizophrenia, acute treatment of manic and mixed episodes associated with bipolar I disorder and adjunctive treatment for depression.

Genetic risk for schizophrenia, but not bipolar disorder, was associated with poorer neuromotor development in infancy, according to recent findings.

Mendelian randomization assumptions indicated C-reactive protein had a protective effect on risk for schizophrenia, while soluble interleukin-6 receptor increased risk.

Alkermes recently announced submission of a New Drug Application for aripiprazole lauroxil NanoCrystal Dispersion, an investigational product designed for initiation to Aristada extended-release injectable suspension, for treatment of schizophrenia.

Indivior recently submitted a New Drug Application to the FDA for marketing approval of RBP-7000, a once-monthly injectable risperidone in the Atrigel delivery system, for schizophrenia, according to a manufacturer-issued press release.

Analysis of nationwide twin data from Denmark estimated heritability of schizophrenia at 79%, indicating a significant genetic risk.

Recent findings suggested dopamine synthesis capacity as a potential drug target for bipolar disorder and schizophrenia.

Efficacy of Aristada continued for 1 year among individuals successfully treated for an acute episode of schizophrenia, according to recent findings.